EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?

César Fernández-de-Las-Peñas iD, Anabel Franco-Moreno, María Ruiz-Ruigómez iD, Estibaliz Arrieta-Ortubay, Pablo Ryan-Murua iD, Carlos Lumbreras-Bermejo, Pablo Del-Valle-Loarte iD, Oscar J Pellicer-Valero iD, Rocco Giordano iD, Lars Arendt-Nielsen, Isabel Martín-Garrido, Juan Torres-Macho iD

Viruses · 2024

DOI: 10.3390/v16060947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von César Fernández-de-Las-Peñas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, 28922 Madrid, Spain. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comunidad de Madrid, Novo Nordisk Foundation, Fondo Europeo De Desarrollo Regional—Recursos REACT-UE del Programa Operativo de Madrid 2014–2020, en la línea de actuación de proyectos de I+D+i en materia de….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to investigate the effects of administrating Remdesivir at the acute COVID-19 phase on developing post-COVID symptoms in previously hospitalized COVID-19 survivors by controlling factors such as age, sex, body mass index, and vaccination status. A case-control study was performed. Hospitalized COVID-19 survivors who had received intravenous Remdesivir during the acute phase (n = 216) were matched by age, sex, body mass index, and vaccination status with survivors who did not receive antiviral treatment (n = 216). Participants were asked to self-report the presence of any post-COVID symptom (defined as a symptom that started no later than three months after infection) and whether the symptom persisted at the time of study (mean: 18.4, SD: 0.8 months). Anxiety levels (HADS-A), depressive symptoms (HADS-D), sleep quality (PSQI), and severity/disability (FIC) were also compared. The multivariate analysis revealed that administration of Remdesivir at the acute COVID-19 phase was a protective factor for long-term COVID development (OR0.401, 95%CI 0.256–0.628) and specifically for the following post-COVID symptoms: fatigue (OR0.399, 95%CI 0.270–0.590), pain (OR0.368, 95% CI 0.248–0.548), dyspnea at rest (OR0.580, 95%CI 0.361–0.933), concentration loss (OR0.368, 95%CI 0.151–0.901), memory loss (OR0.399, 95%CI 0.270–0.590), hair loss (OR0.103, 95%CI 0.052–0.207), and skin rashes (OR0.037, 95%CI 0.005–0.278). This study supports the potential protective role of intravenous administration of Remdesivir during the COVID-19 acute phase for long-lasting post-COVID symptoms in previously hospitalized COVID-19 survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineAdenosine MonophosphateAntiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2COVID-19HumansFemaleMaleMiddle AgedCase-Control StudiesPost-Acute COVID-19 SyndromeAdultAged

Stichwörter der Autor:innen

antivirallong-COVIDpost-COVID-19remdesivir

Substanzen

remdesivirAlanineAdenosine MonophosphateAntiviral Agents

Autor:innen und Institutionen

  • Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, 28922 Madrid, Spain.
  • Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark.
  • Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.
  • Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Investigación Carlos III (ISCIIII), 28220 Madrid, Spain.
  • Department of Internal Medicine, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain.

ORCID-Profile: César Fernández-de-Las-Peñas, María Ruiz-Ruigómez, Pablo Ryan-Murua, Pablo Del-Valle-Loarte, Oscar J Pellicer-Valero, Rocco Giordano, Juan Torres-Macho

Förderung

  • Comunidad de Madrid
  • Novo Nordisk Foundation
  • Fondo Europeo De Desarrollo Regional—Recursos REACT-UE del Programa Operativo de Madrid 2014–2020, en la línea de actuación de proyectos de I+D+i en materia de…

Zitieren

APA

Fernández-de-Las-Peñas, C., Franco-Moreno, A., Ruiz-Ruigómez, M., Arrieta-Ortubay, E., Ryan-Murua, P., Lumbreras-Bermejo, C., Del-Valle-Loarte, P., Pellicer-Valero, O. J., Giordano, R., Arendt-Nielsen, L., Martín-Garrido, I., & Torres-Macho, J. (2024). Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?. Viruses. https://doi.org/10.3390/v16060947

Vancouver

Fernández-de-Las-Peñas C, Franco-Moreno A, Ruiz-Ruigómez M, Arrieta-Ortubay E, Ryan-Murua P, Lumbreras-Bermejo C, et al. Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?. Viruses. 2024. doi:10.3390/v16060947

BibTeX
@article{FernndezdeLasPeas2024,
  author = {Fernández-de-Las-Peñas, César and Franco-Moreno, Anabel and Ruiz-Ruigómez, María and Arrieta-Ortubay, Estibaliz and Ryan-Murua, Pablo and Lumbreras-Bermejo, Carlos and Del-Valle-Loarte, Pablo and Pellicer-Valero, Oscar J and Giordano, Rocco and Arendt-Nielsen, Lars and Martín-Garrido, Isabel and Torres-Macho, Juan},
  title = {Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16060947}
}
Kostenlos starten →